Showing results (1-10 of 152) with videos related to
Sort By:
Pageof 16
Expert Opinion on Pharmacotherapy|March 21, 2024
Upadacitinib in Crohn's diseaseAxel Dignass, Philip Esters, Cathrin FlauausCurrent Drug Targets|September 4, 2014
Complementary therapies in inflammatory bowel diseasesPhilip Esters, Axel DignassScandinavian Journal of Gastroenterology|March 22, 2018
A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patientsHermann Schulze, Philip Esters, Franz Hartmann, et al.United European Gastroenterology Journal|June 26, 2020
Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's diseaseWolfgang Alexander Seeger, Juliane Thieringer, Philip Esters, et al.International Journal of Chronic Diseases|May 11, 2018
Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory ConditionsAxel Dignass, Karima Farrag, Jürgen SteinCurrent Medical Research and Opinion|December 21, 2011
Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originatorJürgen Stein, Axel Dignass, Kai Uwe ChowZeitschrift Fur Gastroenterologie|June 16, 2025
From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitisElisabeth Schnoy, Axel Dignass, Matthew Gaskins, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 20, 2007
Sexual function in persons with inflammatory bowel disease: a survey with matched controlsAntje Timmer, Alexandra Bauer, Axel Dignass, et al.Innere Medizin (Heidelberg, Germany)|January 3, 2025
[Application of advanced treatment in chronic inflammatory bowel diseases]Benjamin Misselwitz, Sebastian Zeißig, Stefan Schreiber, et al.Alimentary Pharmacology & Therapeutics|June 29, 2023
Review article: Translating STRIDE-II into clinical reality - Opportunities and challengesAxel Dignass, Stefan Rath, Thomas Kleindienst, et al.Pageof 16